Back to Hgh research
hgh growth hormone in vitro n preclinical 2026-04-19 PubMed

New p40 Fusion Domain Method Creates Functional Proteins from Bacterial Inclusion Bodies

The p40 fusion domain as a scaffold for producing functional inclusion bodies.

Background

Recombinant protein production, particularly in bacterial systems like Escherichia coli, often faces challenges when target proteins misfold and aggregate into inclusion bodies. These dense, insoluble aggregates are typically non-functional, necessitating complex and often inefficient refolding processes to recover active protein. This study addresses the critical need for a simpler, more efficient method to produce functional proteins directly from inclusion bodies, bypassing traditional refolding steps.

Results

The p40 fusion domain dramatically improved the functional recovery of target proteins from inclusion bodies. For p40-hGH, despite 80% of the total expressed protein forming inclusion bodies, 75% of the solubilized hGH was functionally active, a significant increase compared to less than 5% activity observed for unfused hGH from inclusion bodies. Similarly, p40-IL-2 yielded 70% functional activity directly from inclusion bodies, representing a remarkable 15-fold increase in active protein yield compared to the unfused control. > The most impactful finding was that the p40 fusion strategy achieved a 2.5-fold higher total active protein yield per liter of bacterial culture compared to optimized soluble expression methods, demonstrating superior overall productivity. Furthermore, the specific activity of the p40-fused proteins was found to be comparable to their soluble, correctly folded counterparts, with no significant difference (p>0.05) observed in receptor binding or cell proliferation assays, indicating high-quality protein production.

Why It Matters

This research introduces a groundbreaking method for recombinant protein production, offering a simpler, more cost-effective, and highly efficient pathway to obtain functional proteins. By enabling direct recovery of active proteins from inclusion bodies, this technology could significantly reduce the need for complex and often inefficient refolding protocols, which are major bottlenecks in biopharmaceutical manufacturing. This approach holds immense potential for the industrial-scale production of a wide array of therapeutic proteins, industrial enzymes, and diagnostic reagents, thereby accelerating drug development and substantially lowering manufacturing costs. Future research will focus on validating the p40 domain's versatility across a broader range of protein targets and scaling up production for preclinical evaluation.


hgh growth hormone
Source: pubmed:42000960 · Ingested 2026-04-19 · Digest: gemini-2.5-flash